TABLE 2.

Multivariate analysis in the ALL group

	n	%	Univariate		Multivariate
			HR (95% CI)	p value	HR (95% CI)	p value
(A) PFS
AI fit/unfit	337/113	74.9/25.1	0.73 (0.57–0.92)	0.007	0.75 (0.59–0.95)	0.018
Age (<74/≧75)	314/136	69.8/30.2	1.08 (0.86–1.35)	0.519	1.04 (0.83–1.31)	0.731
Sex (male/female)	157/293	34.9/65.1	1.34 (1.08–1.66)	0.007	1.22 (0.92–1.61)	0.172
Stage (relapse, IIIB/IV)	136/314	30.2/69.7	0.58 (0.46–0.74)	<0.001	0.57 (0.45–0.72)	<0.001
PS (0,1/2)	377/73	83.8/16.2	0.59 (0.45–0.79)	<0.001	0.56 (0.42–0.75)	<0.001
Smoke (former, current/never)	256/194	56.9/43.1	1.29 (1.05–1.59)	0.015	1.15 (0.88–1.51)	0.308
EGFR (L858R/19 del)	206/244	45.8/54.2	1.15 (0.93–1.41)	0.191	1.18 (0.96–1.45)	0.122
TKI (first‐, second‐generation/osimertinib)	389/61	86.4/13.6	1.32 (0.89–1.96)	0.168	1.52 (1.02–2.27)	0.040
(B) OS
AI fit/unfit	337/113	74.9/25.1	0.58 (0.45–0.74)	<0.001	0.60 (0.47–0.77)	<0.001
Age (<74/≧75)	314/136	69.8/30.2	0.75 (0.59–0.96)	0.020	0.74 (0.58–0.95)	0.016
Sex (male/female)	157/293	34.9/65.1	1.51 (1.20–1.89)	<0.001	1.39 (1.02–1.90)	0.038
Stage (relapse, IIIB/IV)	136/314	30.2/69.7	0.71 (0.55–0.91)	0.007	0.71 (0.55–0.92)	0.009
PS (0,1/2)	377/73	83.8/16.2	0.51 (0.38–0.69)	<0.001	0.49 (0.36–0.66)	<0.001
Smoke (former, current/never)	256/194	56.9/43.1	1.34 (1.07–1.68)	0.010	1.18 (0.87–1.61)	0.290
EGFR (L858R/19 del)	206/244	45.8/54.2	1.28 (1.03–1.60)	0.029	1.33 (1.06–1.66)	0.014
TKI (first‐, second‐generation/osimertinib)	389/61	86.4/13.6	1.20 (0.68–2.12)	0.537	1.24 (0.70–2.21)	0.455

Abbreviations: 19 del, exon 19 deletion; CI, confidence interval; EGFR, epidermal growth factor receptor; first‐, second‐generation, gefitinib, erlotinib, and afatinib; HR, hazard ratio; PFS, progression‐free survival; PS, performance status; TKI, tyrosine kinase inhibitor.

Bold values are p <0.05, which is statistically significant.